2. Erythrocytes copy

Page 1: Production of Red Blood Cells

Development Changes

  • As red blood cells (RBCs) mature:

    • They fill with hemoglobin to a concentration of about 34%.

    • The nucleus condenses and is eventually absorbed or extruded from the cell.

    • The endoplasmic reticulum is also reabsorbed.

  • At this stage, these cells are termed reticulocytes due to the remaining basophilic material, which includes remnants of the Golgi apparatus, mitochondria, and a few other cytoplasmic organelles.

Transition to Maturity

  • Reticulocytes enter the bloodstream from the bone marrow through a process called diapedesis.

  • The basophilic material fades within 1 to 2 days, leading to the final form as mature erythrocytes.

  • Reticulocytes represent less than 1% of all RBCs due to their short lifespan.


Page 2: Erythropoietin Regulates Red Blood Cell Production

Regulation of RBC Mass

  • The total mass of RBCs is tightly regulated to:

    • Ensure sufficient transport of oxygen from the lungs to tissues.

    • Prevent excessive numbers of cells that could block blood flow.


Page 3: Tissue Oxygenation and RBC Production

Oxygen Levels

  • Decreased oxygen transport to tissues typically triggers an increase in RBC production.


Page 4: Erythropoietin and Hypoxia

Erythropoietin as a Stimulus

  • Erythropoietin (EPO), a circulating hormone, is the primary stimulator for RBC production in hypoxic conditions.

    • It is a glycoprotein with a molecular weight around 34,000.

  • Without EPO, hypoxia has minimal effect on stimulating RBC production.


Page 5: Erythropoietin Production Location

Formation Sites

  • Approximately 90% of EPO is produced in the kidneys, with the remainder formed mainly in the liver.

  • Renal hypoxia elevates hypoxia-inducible factor-1 (HIF-1), which influences the transcription of EPO and other hypoxia-inducible genes, driving increased EPO synthesis.


Page 6: EPO Regulation Mechanism

Feedback Mechanism

  1. Stimulus: Decreased blood oxygen levels.

  2. Detection: Kidneys detect low O2, inhibiting EPO release through negative feedback.

  3. EPO Release: Kidney cells release EPO into the bloodstream.

  4. Effectors: EPO stimulates red bone marrow, increasing erythrocyte production.

  5. Net Effect: Elevated erythrocyte numbers enhance blood O2 levels.


Page 7: EPO Binding and Effects

Interaction with EPO Receptor

  • EPO (ligand) binds to its receptor (EPOR) on the surface of immature erythroid cells, initiating a signal that leads to:

    • Increased cell division and maturation.

    • Augmented intestinal iron absorption and hemoglobin production.

    • More RBCs entering circulation.


Page 8: EPO Sensitivity

Varying EPO Sensitivity

  • EPO-responsive cells' sensitivity varies:

    • Some cells respond to low EPO levels; others require higher EPO levels.

  • Under stable erythropoiesis, only low EPO levels suffice, while higher EPO levels due to hypoxia mobilize a broader range of responsive cells.


Page 9: Hypoxia and Kidney Response

Nonrenal Stimuli

  • Hypoxic conditions in tissues other than the kidneys can stimulate erythropoietin secretion from the kidneys, suggesting nonrenal sensors may exist.

  • Factors like norepinephrine, epinephrine, and prostaglandins promote EPO production.

  • Removal or failure of both kidneys results in significant anemia due to insufficient EPO production from other tissues, primarily the liver.


Page 10: EPO Role in Bone Marrow

Timeframe and Effects

  • In response to hypoxia, EPO levels rise within minutes to hours and peak within 24 hours.

  • RBCs do not appear in the circulation immediately; it takes about 5 days post-EPO effect for mature cells to emerge.

  • EPO primarily stimulates the production of proerythroblasts from hematopoietic stem cells in the bone marrow.

  • It accelerates the cell's transition through the erythroblastic stages, enhancing RBC production rates.


Page 11: EPO and RBC Production Rate

EPO Impact on Production

  • In the absence of EPO, minimal RBCs are produced.

  • With high EPO levels in nutrient-rich conditions, RBC production can increase up to 10 times normal.

  • EPO's regulatory mechanism for RBC production is potent.


Page 12: Nutritional Influence on RBC Maturation

Importance of Nutrition

  • Erythropoietic cells in bone marrow are some of the fastest-growing in the body, heavily influenced by nutritional status.


Page 13: Essential Vitamins for Maturation

Key Nutrients

  • Vitamin B12 (Cyanocobalamin) and Folic Acid are crucial for RBC maturation as they are required for DNA synthesis.

  • Deficiencies in either vitamin lead to abnormal DNA synthesis, hinder nuclear maturation, and reduce cell division.


Page 14: Macrocyte Formation

Consequence of Vitamin Deficiency

  • Erythroblasts in vitamin-deficient conditions yield larger than normal RBCs, termed macrocytes.

  • Macrocytes have fragile membranes, leading to a reduced lifespan compared to typical erythrocytes.


Page 15: Pernicious Anemia

Absorption Failure of B12

  • Pernicious anemia is often due to failure in the gastrointestinal absorption of vitamin B12, often linked with atrophic gastric mucosa lacking intrinsic factor.


Page 16: Folic Acid Deficiency

Sources and Common Issues

  • Folic acid, present in green vegetables, fruits, and meats, is susceptible to destruction during cooking.

  • Absorption issues, as seen in conditions like sprue, complicate intake of both folic acid and vitamin B12.


Page 17: Factors Controlling Erythropoiesis

Categories of Influences

  • Erythropoiesis is controlled by three primary factors:

    • Hormonal

    • Dietary

    • Other factors that affect production.


Page 18: Life Span of RBCs

Circulation Duration

  • RBCs typically last about 120 days in circulation before undergoing destruction, primarily in the spleen and liver.


Page 19: RBC Functionality

RBC Composition

  • Although mature RBCs lack a nucleus, mitochondria, or endoplasmic reticulum, they retain cytoplasmic enzymes that facilitate glucose metabolism and the formation of ATP. These enzymes maintain:

    1. Cell membrane pliability.

    2. Membrane transport of ions.

    3. Iron in hemoglobin as ferrous rather than ferric.

    4. Prevention of protein oxidation in RBCs.


Page 20: Aging and Fragility of RBCs

Aging Process

  • Old RBCs experience declining metabolic activity, leading to increased fragility.

  • Fragile membranes can rupture when passing through narrow circulatory points.

  • Many RBCs self-destruct in the spleen during this passage.

  • Removal of the spleen results in an increased count of abnormal aged RBCs circulating in the blood.


Page 21: Blood Types and Transfusion


Page 22: Blood Antigens

Antigen Complexity

  • Human blood cells possess at least 30 common antigens and hundreds of rare antigens that can elicit antigen-antibody reactions.

  • The O-A-B system and the Rh system are most critical concerning transfusion reactions.


Page 23: A and B Antigens

Characteristics of Antigens

  • Type A and B antigens (agglutinogens) are complex oligosaccharides differing by terminal sugars.

  • An H gene encodes a transferase that forms H antigen.

  • Variations are presented in individuals:

    • Type A: has N-acetylgalactosamine.

    • Type B: has galactose.

    • Type AB: has both.

    • Type O: lacks both, retaining only H antigen.


Page 24: Agglutinogens and Reactions

Role in Transfusion

  • A and B antigens are often responsible for transfusion reactions due to agglutination properties.

  • Inheritance patterns can yield no antigen, one antigen, or both.


Page 25: Major O-A-B Blood Types

Classification

  • Blood types are categorized based on the presence of A and B agglutinogens:

    • Type O: absent both A and B.

    • Type A: present A only.

    • Type B: present B only.

    • Type AB: present both A and B.


Page 26: Agglutinin Development

Antibodies in Plasma

  • The absence of type A agglutinogens leads to the development of anti-A agglutinins; type B absence leads to anti-B agglutinins.

  • Type O individuals develop both anti-A and anti-B; type A develops anti-B, and type B develops anti-A; type AB has no agglutinins.


Page 27: Agglutinin Development by Age

Timeline of Development

  • At birth, agglutinin levels are nearly zero.

  • By 2 to 8 months, an infant begins producing agglutinins, peaking at 8 to 10 years before gradually declining.


Page 28: Origin of Agglutinins

Production Sources

  • Agglutinins are gamma globulins, produced by bone marrow and lymph nodes, similar to antibodies for other antigens.

  • Small amounts of A and B antigens from food and bacteria may trigger antibody production against non-present agglutinogens.


Page 29: Agglutination Mechanism

Reaction Process

  • When mismatched blood is mixed, anti-A or anti-B agglutinins react with corresponding RBC agglutinogens, causing RBC agglutination.

  • Agglutinins with multiple binding sites can link RBCs, causing clumping.


Page 30: Outcomes of Agglutination

Consequences of Clumping

  • Agglutinated cells can obstruct blood vessels within circulation.

  • Over time, agglutinated cells may undergo hemolysis; the released hemoglobin is converted to bilirubin.


Page 31: Universal Donors and Recipients

Type O and AB Characters

  • Type O blood (lacking A and B antigens) can transfuse to any blood type but should be administered carefully to limit plasma volume.

  • Type AB individuals can receive any type of blood due to the absence of agglutinins, making them universal recipients, albeit with plasma cautions.


Page 32: Precautions in Transfusion

Importance of Cross-Matching

  • Blood transfusions require matching to avoid reactions; emergency procedures may utilize universal donor principles but are dangerous without cross-matching.

  • Cross-matching involves mixing donor RBCs with recipient plasma to observe for agglutination.


Page 33: Acute Hemolysis Overview

Immediate Reactions

  • Mismatches can cause immediate hemolysis through complement activation and lysis processes.

  • Immediate reactions are less common than delayed ones and typically require specific antibodies called hemolysins.


Page 34: Blood Typing Process

Typing Procedures

  • Blood typing involves separating RBCs and mixing them with anti-A and anti-B agglutinins, observing for agglutination to identify blood types.


Page 35: Rh Blood Types Overview

Rh System Significance

  • Rh blood types are crucial along with O-A-B types; spontaneous Rh agglutinins are rare and typically result from prior exposure to Rh antigens.


Page 36: Rh Antigens

Variants of Rh Factors

  • Six primary types of Rh antigens (C, D, E, c, d, e); individuals have pairs of these antigens according to shared inheritance patterns.


Page 37: Rh Positive vs. Negative

Characteristics of Rh Blood

  • Type D is the prominent Rh antigen; Rh-positive individuals possess it while Rh-negative individuals do not.

  • Rh-negative individuals may react to other Rh antigens, albeit with milder severity.


Page 38: Immune Response to Rh

Sensitization Mechanics

  • When Rh-positive RBCs enter an Rh-negative individual, anti-Rh antibodies develop over 2-4 months, leading to potential sensitization after multiple exposures.


Page 39: Characteristics of Rh Reactions

Delayed Reactions

  • An Rh-negative individual may not experience immediate reactions after receiving Rh-positive blood, but delayed reactions can occur due to antibody buildup, leading to hemolysis by tissue macrophages.


Page 40: Erythroblastosis Fetalis Definition

Description

  • Erythroblastosis fetalis involves agglutination and destruction of fetal RBCs, presenting significant clinical concerns.


Page 41: Incidence in Newborns

Risk Factors

  • First pregnancies of Rh-negative mothers with Rh-positive babies typically show minimal risk; however, subsequent pregnancies increase the likelihood of erythroblastosis fetalis.


Page 42: Maternal Antibodies Impact

Effects on Fetus

  • Maternal anti-Rh antibodies can cross the placenta, agglutinating fetal blood and causing hemolysis, leading to jaundice from bilirubin release.


Page 43: Clinical Picture

Symptoms Presentation

  • Newborns with erythroblastosis may present with jaundice and severe anemia at birth, with maternal antibodies persisting for months causing ongoing RBC destruction.


Page 44: Rapid RBC Production

Disease Progression

  • The fetus's rapid RBC production (including immature cells) can lead to erythroblastosis fetalis; bilirubin-related brain damage may occur, raising concerns for kernicterus.


Page 45: Treatment Options

Blood Replacement Therapy

  • Treatment includes exchanging neonatal blood with Rh-negative blood, repeated as needed to manage bilirubin levels and reduce kernicterus risks.


Page 46: Prevention Strategies

Use of Rh Immunoglobulin

  • Rh immunoglobulin administration to Rh-negative mothers has significantly reduced erythroblastosis incidences since the 1970s, preventing sensitization by targeting D antigen exposure.


Page 47: Mechanisms of Action

Immunological Interference

  • The exact mechanism of Rh immunoglobulin is unclear; it inhibits B lymphocyte antibody production against Rh antigens and neutralizes Rh-positive fetal RBC antigens that enter the mother's circulation.


Page 48: Reaction Mechanism

Transfusion Risks

  • Mismatched blood transfusions generally lead to agglutination, although immediate reactions are limited due to dilution effects.


Page 49: Consequences of Hemolysis

Symptoms and Outcomes

  • Transfusion reactions lead to hemolysis, increased bilirubin levels resulting in jaundice if significant RBC destruction occurs.


Page 50: Kidney Failure Risks

Lethal Consequences

  • Transfusion reactions can cause acute kidney failure due to antigen-antibody reactions causing renal damage and systemic shock.


Page 51: Kidney Shutdown Mechanism

Factors Leading to Failure

  • Kidney failure from transfusion reactions results from:

    1. Toxic substances from hemolysis causing vasoconstriction.

    2. Loss of RBCs leading to circulatory shock.

    3. Excess hemoglobin causing tubular obstruction and subsequent renal shutdown.